West African Crystalline Retinopathy

West African Crystalline Retinopathy is a rare eye condition seen mostly in people of West African origin. Doctors see tiny, shiny, yellow-green “crystals” clustered at the very center of the retina (the macula/fovea). These crystals are small, refract light, and often look like glistening dots. Most patients do not notice any vision problem, and the rest of the eye exam can be normal. The cause is still uncertain. The condition is usually harmless, and the crystals can stay the same, increase for a while, or slowly fade over years. Fluorescein angiography and fundus autofluorescence are often normal, and optical coherence tomography (OCT) shows the crystals sitting within the retina (inner layers or around Henle’s fiber layer/outer plexiform region). JAMA Network+1PubMedEyeWiki

West African Crystalline Retinopathy is a rare eye condition where tiny, shiny, yellow-green crystals collect in the center of the retina (the macula, the area you use to read and see fine detail). Doctors often discover these crystals during a routine eye exam. Many people have no symptoms, and vision may be normal. On modern scans (OCT), the crystals sit in the inner layers of the retina, right at the fovea (the very center). JAMA NetworkPubMedPMC

Key points in simple words:

• It is rare and mostly reported in West Africans or their descendants.

• The tiny crystals sit at or near the fovea (the sharpest seeing part of the retina).

• Vision is often normal unless there is another eye disease at the same time (like diabetic macular edema).

• Cause is unknown. Some studies suggest long-term diet or vascular “leakiness” may help crystals form. EyeWikiJAMA NetworkOphthalmology Retina

---

Types

There is no official staging system, but these practical categories help describe what you see and plan work-up. (These are descriptive types used by clinicians; they are not formal pathologic subtypes.)

1. By laterality

• Bilateral (both eyes): the most common pattern; often asymmetric (one eye more than the other).

• Unilateral (one eye): less common and sometimes linked with a local retinal issue in that eye. JAMA NetworkEyeWiki

2. By symmetry

• Asymmetric: typical—one eye carries a denser cluster of crystals.

• Symmetric: less common; similar crystal load in both eyes. EyeWiki

3. By density/distribution of crystals (clinical description)

• Sparse foveal cluster: few crystals at foveal center.

• Moderate foveocentric cluster: more crystals confined to fovea.

• Foveal + parafoveal scatter: crystals at fovea with a light scatter around it; still within macula; not extending beyond temporal arcades (helps distinguish from other crystalline retinopathies). EyeWiki

4. By retinal layer localization on OCT

• Inner retinal localization (including near the internal limiting membrane).

• Henle’s fiber layer / outer plexiform region localization.

• Mixed/uncertain localization (depends on OCT resolution and angle). EyeWiki

5. By association with vascular disease

• With diabetic retinopathy (± macular edema).

• With sickle cell retinopathy or retinal vein occlusion.

• Without obvious vascular disease (idiopathic pattern). EyeWikiPMC

6. By course over time

• Stable crystal load.

• Evolving (increase over months, then plateau).

• Regressing (slow spontaneous reduction over years). EyeWiki

---

Causes or contributors

Important: The true cause is unknown. The items below are hypotheses, associations, or co-factors reported in the literature. They help guide history-taking and exclusion of other “crystalline” diseases.

1. Dietary exposure—kola nut (long-term chewing). Proposed in early reports; not consistent in all patients. Think of it as a possible long-term exposure, not a proven cause. PMCJAMA Network

2. Other traditional/West African foods (cassava, palm oil, certain greens). Reported in histories; evidence inconsistent. EyeWiki

3. Breakdown of the blood–retinal barrier (BRB) from coexisting retinal vascular disease—this may let circulating compounds enter the retina and crystallize. Ophthalmology RetinaPubMed

4. Diabetic retinopathy (especially with macular edema or prior laser): frequently co-present; thought to “promote” deposition by BRB leakage. PubMed

5. Sickle cell retinopathy: reported cases show coexistence, supporting a vascular-leak hypothesis. PMC

6. Retinal vein occlusion: another vascular-leak setting occasionally seen with these crystals. EyeWiki

7. Familial exudative vitreoretinopathy (FEVR): a vascular developmental disorder occasionally reported in association. EyeWiki

8. Uveitis in one eye: can explain unilateral/asymmetric cases (local inflammation → local barrier breakdown). EyeWiki

9. Age-related degenerative changes: most patients present in their 40s–70s; age may make the macula more vulnerable to deposition. EyeWiki

10. Genetic predisposition: family members usually normal, but ethnicity-linked susceptibility is suspected (not proven). EyeWiki

11. Prior general anesthesia or specific anesthetic exposures (historical notes in some cases; not proven). EyeWiki

12. Past malaria treatments (e.g., chloroquine) or toxic-chloroquine exposure: mentioned in histories; causation unproven. EyeWiki

13. Other medications historically tied to crystalline maculopathies (tamoxifen, canthaxanthine, nitrofurantoin, methoxyflurane): mostly included to exclude drug-induced crystalline maculopathy that can mimic WACR. EyeWiki

14. Idiopathic lipid exudation near the fovea: crystals sometimes co-localize with lipid exudates; may act as a “scaffold.” EyeWiki

15. Chronic macular edema of any cause: prolonged extracellular fluid may let solutes deposit. (Mechanistic inference aligned with BRB hypothesis.) Ophthalmology Retina

16. Retinal laser history in diabetic eye disease: some case observations suggest crystal load can change when the macular fluid status changes post-treatment. PubMed

17. Environmental factors (long-term dietary or regional exposures over years): suspected due to geographic clustering. JAMA Network

18. Oxidative stress / altered lipid handling in macula (hypothesized in crystalline retinopathies generally; not specific to WACR). EyeWiki

19. Müller cell dysfunction leading to inner BRB disruption (pathophysiology hypothesis). EyeWiki

20. Unknown endogenous metabolites that crystallize in foveal tissue in susceptible individuals (current open question). JAMA Network

---

Symptoms

Most patients are asymptomatic. When symptoms occur, they usually result from another macular problem (like diabetic macular edema) that is present at the same time.

1. No symptoms (most common). JAMA Network

2. Mild blurred vision (usually from coexisting macular edema or exudates, not the crystals themselves). EyeWiki

3. Reduced reading clarity (macular fluid or exudates affecting fine print). EyeWiki

4. Mild distortion of straight lines (if macula is swollen from another cause). EyeWiki

5. Fluctuating central vision with changes in macular edema. PubMed

6. Decreased contrast sensitivity (nonspecific).

7. Glare sensitivity (nonspecific).

8. Difficulty in dim light (usually if there is additional retinal disease).

9. Color vision usually normal (important negative symptom). JAMA Network

10. Peripheral vision unaffected (crystals are foveocentric). EyeWiki

11. No photopsias expected from the crystals themselves (nonspecific if present).

12. No pain (retinal condition).

13. No redness (posterior segment condition).

14. No floaters specifically from the crystals (floaters would point to vitreous issues).

15. Stable symptoms over long periods unless the associated vascular disease changes. EyeWiki

---

Diagnostic tests

A) Physical examination (at the slit lamp + dilated fundus exam)

1. Best-corrected visual acuity (BCVA)
   Checks how well the patient sees with proper glasses. In WACR, vision is often normal unless there is another macular disease (like diabetic edema). JAMA Network

2. Pupil exam
   Looks for afferent defects; usually normal in WACR unless other optic/retinal pathology exists.

3. Intraocular pressure (IOP)
   Screens for glaucoma; not directly related to WACR but important for comprehensive care.

4. Anterior segment exam
   Rules out anterior uveitis or corneal crystals (important for differential diagnosis).

5. Dilated fundus biomicroscopy
   Core test: the examiner sees tiny, birefringent, yellow-green crystals at the fovea, often in clusters; commonly bilateral but asymmetric. JAMA NetworkEyeWiki

6. Color vision testing
   Usually normal—helps separate WACR from diseases that reduce macular color function (important “normal” finding in early descriptions). JAMA Network

7. Humphrey visual field (central 10-2 or 24-2)
   Often normal; useful baseline and to detect comorbid disease. JAMA Network

B) Manual / bedside tests

8. Amsler grid
   At-home or in-clinic check for distortion. Distortion suggests macular edema or other maculopathy rather than crystals themselves.

9. Pinhole test
   Distinguishes optical blur from retinal causes; helpful when vision is slightly reduced.

10. Near-vision reading chart
    Practical gauge of central function for daily tasks; useful to correlate with BCVA.

C) Laboratory & pathological tests (mainly to exclude look-alikes)

These tests do not diagnose WACR directly; they help rule out other crystalline retinopathies (drug-induced or metabolic/genetic).

11. Medication review + drug screening when appropriate
    Rule out tamoxifen, canthaxanthine, nitrofurantoin, methoxyflurane, and talc (IV drug use)—common causes of crystalline maculopathy that can mimic WACR. EyeWiki

12. Fasting glucose & HbA1c
    Check for diabetes and control level, because diabetic retinopathy is a frequent associate and may “promote” crystals via BRB breakdown. PubMed

13. Hemoglobin electrophoresis
    Look for sickle cell disease/trait if the history suggests it, because cases were reported with sickle cell retinopathy. PMC

14. Basic lipid panel
    Helps identify systemic lipid issues that might increase macular exudation (not a cause of WACR, but relevant to comorbid maculopathy).

15. Serum/urine oxalate; renal function
    To exclude primary hyperoxaluria/oxalosis, a systemic crystalline disease that can deposit in retina (differential diagnosis). EyeWiki

16. Lysosomal storage / cystinosis screening (selected cases)
    To exclude cystinosis (a crystal-forming systemic disease in the differential). EyeWiki

D) Electrodiagnostic tests

17. Full-field ERG
    Usually normal in WACR; in the original series, one patient had mild, unexplained reductions. Normal ERG supports the “innocuous” nature when macula looks crystalline but retina functions broadly okay. JAMA Network

18. Multifocal ERG (mfERG)
    Can quantify macular function if vision complaints exist; typically near-normal unless comorbid disease is present (helps separate effect of edema vs crystals).

19. Electro-oculogram (EOG)
    Occasionally used if a degenerative maculopathy is suspected; usually not necessary in classic WACR.

E) Imaging tests (cornerstone for diagnosis and for excluding mimics)

20. Color fundus photography
    Documents the shiny yellow-green crystals at the fovea and monitors change over time. JAMA Network

21. Optical coherence tomography (OCT)
    Key test. Shows small, hyper-reflective foci in the inner retina or Henle’s/outer plexiform region; macular thickness helps detect any edema from co-disease. EyeWikiLippincott Journals

22. Polarized light/rotating polarizing filter during imaging or exam
    Shows birefringence, which explains the glistening look and supports the crystalline nature. EyeWiki

23. Fundus autofluorescence (FAF)
    Usually normal over the crystals—this helps differentiate from lipofuscin-rich lesions. PubMed

24. Fluorescein angiography (FA)
    Often unremarkable over the crystals; may show leakage only if there is an associated vascular problem (e.g., diabetic neovascularization). JAMA NetworkEyeWiki

25. OCT-Angiography (OCT-A)
    Non-invasive map of foveal capillaries; crystals lie in the foveal avascular zone and do not create flow voids; useful to document coexisting microvascular disease. EyeWiki

26. Near-infrared reflectance / multicolor confocal scanning laser
    Often highlights the crystals as bright, reflective dots and complements color photos and OCT. PubMed

Non-pharmacological treatments (therapies and “other”)

Important: There is no proven, crystal-clearing treatment for WACR itself. Care focuses on safe monitoring, removing possible triggers, and managing co-existing eye disease. Below are practical, clinic-style actions you and your clinician can use. I list the description, the purpose, and a plain mechanism for each.

1. Regular observation with photos + OCT
   Description: Scheduled eye visits (for example every 6–12 months) with retinal photos and OCT scans.
   Purpose: Track whether crystals change and catch any separate problems early.
   Mechanism: Serial imaging shows crystal stability or regression and flags new macular fluid or abnormal vessels in time. PubMed

2. Careful history of diet and exposures
   Description: Review long-term intake of kola products, cassava, palm oil, and similar foods; ask about malaria treatment, chloroquine exposure, or other local factors.
   Purpose: Identify patterns that might contribute and guide reduction if appropriate.
   Mechanism: If an ingested substance contributes to deposition, lowering long-term exposure could reduce crystal load or prevent new deposits (still unproven). EyeWiki

3. Patient education (benign course)
   Description: Explain that WACR is usually asymptomatic with a good outlook.
   Purpose: Reduce anxiety and prevent unnecessary risky treatments.
   Mechanism: Shared knowledge encourages safe monitoring rather than unproven interventions. EyeWiki

4. Manage diabetic health (if present)
   Description: Tight glucose control, BP control, lipid control, renal care.
   Purpose: Reduce risk of diabetic retinopathy progression that can harm vision.
   Mechanism: Better microvascular health lowers leakage and ischemia that could worsen retinal disease. (General diabetes eye-care principle.)

5. Coordinate sickle-cell care (if present)
   Description: Involve hematology; follow sickle cell retinopathy guidelines.
   Purpose: Reduce risk of neovascularization, hemorrhage, and retinal complications.
   Mechanism: Fewer vaso-occlusive events and better oxygenation reduce retinal ischemia and new vessels. PMC

6. Stop smoking
   Description: Smoking cessation support.
   Purpose: Protects retinal circulation and overall vascular health.
   Mechanism: Less oxidative stress and vasoconstriction; lower microvascular injury risk.

7. Medication review
   Description: Review for drugs that cause other crystalline retinopathies (e.g., tamoxifen, high-dose canthaxanthin) and avoid unnecessary exposure.
   Purpose: Prevent confusion with look-alikes and avoid additive retinal risks.
   Mechanism: Removing known retinal toxins reduces crystalline or macular damage from other causes. EyeWiki

8. Treat co-existing retinopathy with laser (PRP) when indicated
   Description: Panretinal photocoagulation if proliferative diabetic or sickle-cell retinopathy is present.
   Purpose: Lower risk of bleeding or retinal detachment from abnormal vessels.
   Mechanism: Laser reduces oxygen demand and promotes regression of fragile neovessels. (Standard for PDR/sickle cell retinopathy, not for crystals themselves.) PMC

9. Macular grid/focal laser—but only for specific comorbid leakage
   Description: Rarely used now (anti-VEGF is preferred), but may be considered for focal diabetic leakage patterns unrelated to crystals.
   Purpose/Mechanism: Seal focal leaks to stabilize macula (comorbidity-specific).

10. Exercise and heart-healthy habits
    Description: Regular activity, healthy weight, BP and lipid control.
    Purpose: Support microvascular retinal health.
    Mechanism: Improves endothelial function and perfusion.

11. Eye-safe nutrition pattern
    Description: Leafy greens, colored fruits/vegetables, fish, whole grains; moderate fats.
    Purpose: Provide carotenoids and antioxidants that support the macula.
    Mechanism: Lutein/zeaxanthin concentrate in the macula and may support retinal resilience (evidence mainly from AMD, not WACR). National Eye Institute

12. Limit heavy kola nut use
    Description: If you consume kola nuts regularly, consider cutting back.
    Purpose: Early papers suspected an association—even though not all cases consumed kola.
    Mechanism: If a dietary compound contributes in some people, reducing exposure removes a potential driver. Evidence is inconsistent, so this is precautionary. PMC+1

13. Consider cassava and palm-oil moderation
    Description: If intake is very high, discuss balanced use.
    Purpose/Mechanism: Precaution based on early associations; later studies are mixed, so the advice is moderate and individualized. JAMA Network

14. Avoid unregulated “retina cleanses” or injections
    Description: Say no to clinics offering crystal-clearing shots or drops.
    Purpose: Prevent harm from unsafe, unapproved products.
    Mechanism: Protects you from complications and vision loss. U.S. Food and Drug Administration

15. Protective eyewear for trauma
    Description: Use sports/occupational eye protection when needed.
    Purpose: Prevents injuries that could complicate retinal health.
    Mechanism: Physical prevention.

16. Hydration and sleep
    Description: Basic wellness steps.
    Purpose/Mechanism: Support overall vascular health and recovery—prudent but not WACR-specific.

17. Sun/UV prudence
    Description: Use sunglasses outdoors.
    Purpose/Mechanism: General retinal comfort and glare reduction (not crystal-specific).

18. Visual function self-checks
    Description: Simple near-reading checks or Amsler-type grid monitoring.
    Purpose: Catch subtle central changes earlier.
    Mechanism: Flags new distortion or blur so you seek care.

19. Keep all medical follow-ups
    Description: Regular visits with retina, diabetes, hematology.
    Purpose/Mechanism: Team care reduces risks from comorbid disease.

20. Document baseline and changes
    Description: Keep copies of your imaging reports.
    Purpose/Mechanism: Helps any new clinician see the long-term pattern and avoid unnecessary procedures.

---

Drug treatments

There is no medicine proven to remove WACR crystals. When doctors use drugs, they target other retinal problems that sometimes occur in the same eye (for example, diabetic macular edema or neovascularization from diabetic or sickle-cell retinopathy). Dosing is by the treating retina specialist and varies by diagnosis and response. Typical examples your doctor may choose:

1. Bevacizumab (anti-VEGF; intravitreal)
   Class & purpose: Anti-VEGF antibody used off-label in the eye to treat macular edema or abnormal new vessels from diseases like diabetic retinopathy or vein occlusion.
   Usual dosing pattern: Commonly 1.25 mg in 0.05 mL by intravitreal injection; intervals often start every 4–6 weeks and then adjust.
   Mechanism: Blocks VEGF to reduce leakage and shrink fragile new vessels.
   Key side effects: Rare infection (endophthalmitis), transient pressure rise, inflammation; systemic risks are very low but discussed with patients. EyeWikiAmerican Academy of Ophthalmology

2. Ranibizumab (anti-VEGF; intravitreal)
   Class & purpose: Anti-VEGF fragment for DME/DR and other retinal vascular diseases.
   Typical dose: 0.3 mg monthly for DME/DR; 0.5 mg monthly for other labeled uses (specialist will tailor).
   Mechanism/side effects: As above for anti-VEGF. FDA Access DataEyeWiki

3. Aflibercept (anti-VEGF/anti-PlGF; intravitreal)
   Class & purpose: VEGF-A/PlGF trap protein for retinal vascular disease.
   Typical dose: 2.0 mg; often after a loading phase, spacing extends to every 8 weeks or via treat-and-extend.
   Mechanism: Strong VEGF binding to control leakage and neovascular growth.
   Side effects: As with intravitreal injections generally. Retina TodayAAO Journal

4. Faricimab (bi-specific anti-VEGF/anti-Ang-2; intravitreal)
   Class & purpose: Targets VEGF-A and Ang-2 to stabilize vasculature in DME/DR.
   Typical dose: Specialist-directed (label-based).
   Mechanism: Dual pathway inhibition may improve durability. (General anti-VEGF class context.)

5. Topical IOP-lowering drops (if pressure rises after injections)
   Purpose: Manage short-term eye-pressure spikes.
   Mechanism: Improve outflow or reduce aqueous production. (General injection care.)

6. Periocular or intravitreal steroids (selected cases of inflammatory edema)
   Purpose: Reduce inflammation-related macular swelling (not WACR crystals).
   Cautions: Can raise eye pressure and speed cataract; specialist decides.

7. Systemic sickle cell therapy (e.g., hydroxyurea; hematology-led)
   Purpose: Lower vaso-occlusive events that worsen sickle-cell retinopathy.
   Note: Managed by hematology; eye benefits are indirect.

8. Systemic risk-factor drugs (antihypertensives, statins, diabetes meds)
   Purpose: Improve vascular health and reduce retinopathy risk.
   Note: Part of comprehensive care.

9. Antiplatelet/anticoagulant therapy (when indicated for systemic issues)
   Purpose: Systemic vascular risk reduction; individualized by primary care/cardiology.

10. Antibiotics/antiseptics for injection prep (clinic use)
    Purpose: Aseptic technique to minimize infection risk with intravitreal therapy.
    Mechanism/notes: Standard-of-care protocols. American Academy of Ophthalmology

---

Dietary molecular supplements

There are no supplements proven to treat WACR. Some patients ask about “eye vitamins.” The only large supplement evidence in retina is for intermediate AMD (not WACR). If you and your doctor decide to try “general macular support,” the AREDS2 formula is the most studied for AMD. I list its nutrients so you can see typical amounts; again, this is not a WACR treatment.

1. Lutein 10 mg/day
   Function: Macular pigment carotenoid; filters blue light.
   Mechanism: Antioxidant concentrated in the macula. (Evidence for slowing AMD progression in intermediate AMD groups.) National Eye Institute+1

2. Zeaxanthin 2 mg/day
   Function/mechanism: Works with lutein as macular pigment. National Eye Institute

3. Vitamin C 500 mg/day
   Function: Antioxidant support (AREDS). National Eye Institute

4. Vitamin E 400 IU/day
   Function: Antioxidant (AREDS).
   Note: Discuss risks if you have certain health conditions. National Eye Institute

5. Zinc (typically 80 mg/day in AREDS; some use 25 mg/day) + copper 2 mg/day
   Function: Enzyme cofactor; copper prevents anemia from high-dose zinc.
   Mechanism: Support retinal antioxidant pathways. National Eye Institute

6. Omega-3 (e.g., fish oil, DHA/EPA; dose individualized)
   Function: General anti-inflammatory lipid support; mixed retinal evidence.
   Mechanism: Cell-membrane and anti-inflammatory effects.

7. Dietary carotenoids from food (spinach, kale, corn, egg yolk)
   Function/mechanism: Food sources of lutein/zeaxanthin; overall diet quality matters. National Eye Institute

8. Multivitamin (no beta-carotene if you are a current/former smoker)
   Function: Broad micronutrient support; avoid beta-carotene due to lung risk in smokers (AMD guidance). National Eye Institute

9. Vitamin D (if deficient; dose per lab tests)
   Function: Systemic health; observational links to eye health exist but are not specific.

10. Resveratrol/anthocyanins (from berries/grapes)
    Function/mechanism: Dietary antioxidants; evidence in WACR is absent; food-first approach is reasonable.

---

Regenerative / stem cell

Short answer: do not pursue stem-cell or “immunity booster” injections for WACR. There is no evidence they help this condition, and unapproved stem-cell eye injections have blinded patients. If anyone offers this to “melt crystals,” treat that as a red flag.

1. Unapproved intravitreal stem-cell injections — avoid
   Why: Multiple patients have suffered severe, permanent vision loss after unregulated “stem-cell” eye injections. New England Journal of MedicineBMJ

2. FDA guidance — heed it
   Why: The FDA warns that most marketed “regenerative” products are unapproved and potentially dangerous outside proper clinical trials. U.S. Food and Drug Administration

3. Clinic claims and “trials” — verify
   Why: Some businesses market pay-to-participate “trials” without approval. Always check clinicaltrials.gov and consult your retina specialist. U.S. Food and Drug Administration+1

4. Systemic “immune boosters” — skepticism
   Why: No data that they change WACR. Focus on general health, sleep, nutrition, exercise.

5. Legit research (other diseases)
   Note: Carefully run stem-cell trials exist for other retinal diseases (e.g., AMD RPE cell work), but that does not translate to WACR—and should never be undertaken outside a regulated trial. The Guardian

6. If you are curious about trials
   Action: Discuss with a retina specialist who can vet real studies and protect your safety.

---

Surgeries / procedures

WACR itself does not require surgery. Procedures below are for co-existing diseases that may appear in the same eye.

1. Panretinal photocoagulation (laser) for proliferative disease
   Why it’s done: To shrink abnormal new vessels in conditions like proliferative diabetic retinopathy or sickle-cell retinopathy.
   How: Thousands of tiny laser spots in the peripheral retina reduce oxygen demand and regress new vessels. PMC

2. Intravitreal anti-VEGF injections (procedural)
   Why: Control leakage or neovascularization due to comorbid retinal vascular disease.
   How: Small office procedure with antisepsis; drug placed inside the eye; repeated as needed. EyeWiki

3. Pars plana vitrectomy
   Why: Clear persistent vitreous hemorrhage, manage tractional detachment from advanced proliferative disease.
   How: Microsurgery to remove vitreous gel and treat traction (for comorbidities—not crystals).

4. Retinal detachment repair (scleral buckle/PPV)
   Why: If a detachment develops from another cause, repair is vision-saving.

5. Glaucoma procedures (e.g., for neovascular glaucoma in sickle-cell or severe diabetes)
   Why: Restore eye-pressure control when standard drops fail.
   How: Laser or filtering surgery as per glaucoma specialist.

---

Preventions

1. Keep regular retina check-ups (photos + OCT). PubMed

2. Control diabetes and blood pressure carefully.

3. Work with hematology if you have sickle-cell disease. PMC

4. Don’t smoke.

5. Eat a balanced, plant-forward diet rich in leafy greens and fish; limit ultra-processed foods. National Eye Institute

6. If you consume kola nuts heavily, consider cutting back (precaution). PMC

7. Moderate very high cassava/palm-oil intake if that applies to you (precaution). JAMA Network

8. Avoid unapproved eye injections or miracle cures. U.S. Food and Drug Administration

9. Protect eyes during risky work/sports.

10. Keep copies of your imaging; bring them to new doctors.

---

When to see a doctor

• Right away if you notice new central blur, wavy lines, a dark curtain, a sudden shower of floaters, flashes of light, eye pain, or red eye—these are not typical of benign crystals and may signal another urgent eye problem.

• Promptly (days) if you see any steady decline in reading, face recognition, or color vision.

• Routinely (every 6–12 months) even if you feel fine, so your doctor can watch stability and treat any separate disease early. EyeWiki

---

What to eat and what to avoid

What to eat (examples):

• Leafy greens (spinach, kale), colored veggies (peppers, carrots), berries, citrus, tomatoes—dietary antioxidants and carotenoids that support the macula (evidence base from AMD, not WACR).

• Fish (e.g., oily fish 1–2×/week) for omega-3s; beans, lentils; whole grains; nuts in moderation; water for hydration. National Eye Institute

What to avoid or limit:

• Heavy, habitual kola nut use; very high cassava/palm-oil intake—especially if long-term and daily (precaution; evidence mixed). PMCJAMA Network

• Smoking and excessive alcohol.

• Unregulated “retina shots,” internet supplements, or “stem-cell cures.” U.S. Food and Drug Administration

---

Frequently Asked Questions

1) Do the crystals damage my sight?
Usually no. Many people keep normal vision, and the condition can stay stable for years. EyeWiki

2) Can the crystals disappear on their own?
They can change and sometimes fade slowly over time; we monitor with photos and OCT. EyeWiki

3) What does the OCT scan show?
Bright little dots (hyper-reflective foci) in the inner layers at the fovea. PubMed

4) Is this caused by kola nuts or cassava?
We’re not sure. Early reports suggested a link; later cases appeared without those foods. Moderation is reasonable, but a direct cause hasn’t been proven. PMC+1

5) Is there a genetic factor?
One study suggested a CFH 402H variant association, but this needs more research. American Academy of Ophthalmology

6) Is there a pill or drop to dissolve the crystals?
No proven medicine exists to remove the crystals. Treatment focuses on careful observation and on other eye problems if they appear. PubMed

7) Will I need shots in the eye?
Only if you develop another condition (like diabetic macular edema or abnormal new vessels). In that case, anti-VEGF injections are routine and given safely in office settings. EyeWiki

8) Are injections safe?
They are common and generally safe, but any eye injection has small risks (infection, inflammation, pressure spikes). Your retina specialist will discuss them and use strict antisepsis. American Academy of Ophthalmology

9) Should I take eye vitamins?
Eye vitamins (AREDS2) help some people with intermediate AMD. For WACR specifically, there’s no proof they help; discuss with your doctor and focus on a nutrient-rich diet first. National Eye Institute

10) Can stem-cell therapy fix this?
No. Unapproved stem-cell eye injections have blinded people. Avoid them outside approved clinical trials. New England Journal of MedicineU.S. Food and Drug Administration

11) How often should I be checked?
If stable, every 6–12 months; sooner if you notice changes. EyeWiki

12) Can diabetes or sickle-cell disease make things worse?
They can cause separate retinal problems that affect vision. Control them carefully and follow specialist care. PMC

13) Do the crystals move?
They usually stay in the central macula; patterns can evolve, and imaging helps us track that. JAMA Network

14) Is this common?
No—WACR is rare. PubMed

15) What’s the single most important thing I can do?
Keep your regular retina visits, and control systemic health (diabetes, blood pressure); avoid unproven treatments. PubMedU.S. Food and Drug Administration

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 30, 2025.